IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
Beta Drugs IPO is a Fixed Price IPO listing on NSE EMERGE exchange, with an ipo size of ₹ 19.52 Cr. The company is based in Baddi and caters to Pharmaceutical sector. Pantomath Capital Advisors is the merchant banker of Beta Drugs IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 28th August 2017.
Beta Drugs IPO open date is 29th September 2017 and close date is 4th October 2017. IPO Allotment Date is 30th November -0001 and Listing date is 12th October 2017.
IPO
Size:
₹ 19.52 Cr.
Avg IPO Size (Sector Based)
: ₹
21.99 cr.
Sector: Pharmaceutical
SME
IPO so far:
40
Merchant Banker:
Pantomath Capital
SME
IPO by BRLM so far:
104
City:
Baddi
SME
IPO so far:
1
Revenue (annualised):
₹
41.68
cr. 
PE
Ratio:
14.00x
Average Sector PE Ratio: 20.74x
Beta Drugs IPO size is ₹ 19.52 Cr. with IPO price of ₹ 85.00. IPO subscription will start on IPO open date and end on IPO close date as per above. IPO valuation metrics can be seen here.
Pantomath Capital Advisors Private Limited is the book-running lead manager of the Beta Drugs IPO. Link Intime India Private Limited is the Registrar and Market Maker is Pantomath Stock Brokers Private Limited for Beta Drugs IPO.
Beta Drugs IPO Draft red herring prospectus (DRHP) and Red Herring prospectus (RHP) are available below.
Beta Drugs IPO, based in Baddi, operates in the Pharmaceutical sector with a focus on manufacturing of its leading anticancer cyto-toxics. The company is launching its SME IPO on the NSE EMERGE exchange, using the Fixed Price Issue method. Beta Drugs IPO size is ₹ 19.52 Cr. with fresh issue size of ₹ 20 and Offer for sale being ₹ Nil
The IPO allotment date for Beta Drugs IPO is expected to be 30th November -0001, after the finalization of basis of allotment. Investors can check Beta Drugs IPO allotment status on the registrars website, Link Intime India Private Limited . Beta Drugs IPO refund dates are 30th November -0001.
Beta Drugs IPO is expected to be listed on 12th October 2017.
The upper price band for the Beta Drugs IPO is set at ₹ 85.00 per equity share. IPO price band is arrived at on the basis of IPO Valuation (P/E multiple) which is mentioned in the RHP.
For IPO analysis on Beta Drugs IPO, explore our Financial Review Page for insights on fundamentals, peer analysis, and key IPO data, assisting investors to make informed decisions to apply or not.
To apply for the Beta Drugs IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of 4th October 2017. After submission, funds are blocked until the basis of allotment of Beta Drugs IPO is finalised.
The merchant banker for Beta Drugs IPO is Pantomath Capital Advisors Private Limited . Pantomath Capital Advisors Private Limited manages the IPO process, including underwriting, regulatory compliance, and investor coordination. Investors can refer to the Beta Drugs IPO RHP for further details.
The registrar for Beta Drugs IPO is Link Intime India Private Limited . Investors can go to Link Intime India Private Limited registrar website for IPO allotment status, refund processing, and other queries related to Beta Drugs IPO through their official website or helpline.
Beta Drugs IPO was subscribed 0.00 times. Stay updated on IPO details, subscription, and allotment news for informed investment decisions.
IPO
Size:
₹ 19.52 Cr.
Avg IPO Size (Sector Based)
:
₹ 21.99 Cr.
Sector: Pharmaceutical
SME
IPO so far:
40
Merchant Banker:
Pantomath Capital
SME
IPO by BRLM so far:
104
City:
Baddi
SME
IPO so far:
1
Revenue (annualised):
₹ 41.65 cr.
PE
Ratio:
14.00x
Average Sector PE Ratio: 20.74x
Beta Drugs IPO may offer opportunites, depending on your investment strategy. For in-depth analysis, risk factors, and KPIs, check our detailed report on Beta Drugs Financial Review Page
Merchant Banker(s) of Beta Drugs IPO: Pantomath Capital Advisors Private Limited
Beta Drugs IPO subscription was 0.00 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Beta Drugs IPO listed at a listing price of 101.95 against the offer price of 85.00.
The current market price of Beta Drugs is 1682.00.
Why Us?
